PBMC-Based Ex Vivo Pulsing Platform for Vaccine Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DC-based vaccines and immunotherapeutics are cumbersome, expensive, and require substantial time and infrastructure, making them difficult to utilize in clinical settings, especially in underdeveloped countries, and have not been applied to prophylactic use or screening of vaccines and adjuvants.
Innovation Solution
The use of peripheral blood mononuclear cells (PBMCs) as a platform for ex-vivo pulsing with antigens and adjuvants, which can replace dendritic cells, providing a simpler, less expensive, and less time-consuming approach for generating protective immune responses, and can be administered via the intranasal route for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells (DCs) are used for vaccine delivery, then immune response efficacy is improved, but process complexity and cost increase substantially
Solution Approach 1:
The patent uses peripheral blood mononuclear cells (PBMCs) as a simplified copy or substitute for dendritic cells. PBMCs contain APC populations including monocytes/macrophages, DCs, and B cells that can process and present vaccine antigens, providing a functional copy of the essential immune-stimulating capability without requiring the complex isolation and differentiation process needed for pure DC preparations.
Solution Approach 2:
PBMCs serve as a universal platform that combines multiple APC functions within a single cell population. The PBMC preparation includes monocytes/macrophages, DCs, and B cells, all capable of processing and presenting vaccine Ags to T cells, thereby providing multi-functional immune stimulation in one preparation rather than requiring separate DC isolation and differentiation steps.
2Reliability
If dendritic cells (DCs) are isolated and differentiated ex vivo, then vaccine delivery efficacy is improved, but time and infrastructure requirements increase
Solution Approach 1:
The patent performs preliminary action by pre-isolating PBMCs from peripheral blood, which contains the necessary APC populations ready for immediate vaccine antigen pulsing. This eliminates the need for time-consuming ex vivo differentiation of DC precursors, as the PBMC preparation already includes mature DCs, monocytes/macrophages, and B cells capable of immediate vaccine delivery.
3Reliability
If dendritic cells (DCs) are used for prophylactic vaccination, then protective immunity is achieved, but cost and infrastructure requirements make deployment difficult in underdeveloped countries
Solution Approach 1:
The patent employs a simpler, more economical PBMC-based system that can be manufactured with minimal infrastructure and expense. The PBMC preparation requires only basic centrifugation and separation techniques rather than complex DC isolation protocols, making it suitable for deployment in underdeveloped countries with limited laboratory resources while still achieving protective immunity.
4Device complexity
If peripheral blood mononuclear cells (PBMCs) are used instead of dendritic cells, then process simplicity and cost reduction are achieved, but immune response efficacy may be compromised
Solution Approach 1:
The patent merges the functions of multiple cell types within the PBMC population to achieve enhanced immune response. By combining monocytes/macrophages, DCs, and B cells in a single PBMC preparation, the system achieves synergistic immune stimulation that compensates for and exceeds the capabilities of any single cell type, including purified DCs.
Solution Approach 2:
The PBMC preparation acts as a composite biological material containing diverse APC populations with complementary functions. This composite cell population includes monocytes/macrophages, DCs, and B cells that work together to process and present vaccine antigens, providing a richer and more versatile immune response than homogeneous DC preparations.
5Reliability
If traditional DC-based vaccine platforms are used, then specific immune responses are achieved, but they cannot serve as a multi-organism vaccine platform
Solution Approach 1:
The PBMC platform provides universality by serving as a multi-organism vaccine platform that can be adapted for various pathogens and vaccine types. The diverse APC populations within PBMCs (monocytes/macrophages, DCs, and B cells) can process and present different vaccine antigens, enabling the same platform to be used for prophylactic vaccination against multiple diseases and for screening candidate vaccines and adjuvants.
Data Source
AI summary
Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.